Skip to main content Skip to search Skip to main navigation

FDA: Patrizia Cavazzoni, M.D., to lead CDER

On 12 April 2021, Dr Janet Woodcock, acting head of the US FDA, announced Dr Patrizia Cavazzoni's new role as director of CDER.

She posted the announcement on her official Twitter account @DrWoodcockFDA. Last year, Cavazzoni succeeded Woodcock as acting head of CDER. As previously reported, Woodcock became committed to Operation Warp Speed (OWS) at that time. 

Cavazzoni joined FDA in January 2018 as acting director of CDER. Prior to that, she held leadership positions at Pfizer as well as other pharmaceutical companies and served as a psychiatrist. 

While Cavazzoni has now been appointed from acting to permanent director, a possible designation of Janet Woodcock as FDA commissioner remains open. 

With President Biden already three months into office, calls are growing louder for a definitive appointment of FDA leadership in the near future.


Source:

Twitter @DrWoodcockFDA

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: New Q&A on Product Lifecycle Management (PLCM)

EMA: New Q&A on Product Lifecycle Management (PLCM)

The EMA has published new Questions & Answers on the use of the Product Lifecycle Management (PLCM) document, clarifying its role within the EU variations framework for post-approval quality changes.
Read more
EMA: New Q&A for Co-Processed Excipients

EMA: New Q&A for Co-Processed Excipients

The EMA has published new Questions & Answers on co-processed excipients (CoPEs) used in solid oral dosage forms, introducing a harmonised, risk-based regulatory approach applicable to human and veterinary medicines.

Read more
What is the Data Lifecycle?

What is the Data Lifecycle?

Here's the answer:
Read more
GMP Regulations Report 2025

GMP Regulations Report 2025

What do the regulatory developments mean for your professional environment? Which requirements have a direct impact on your day-to-day work, and where is there an urgent need for action? Our GMP Regulations Report 2025 provides a clear structure, practical explanations, and the most important regulatory developments of 2025 – concise, well-organized, and relevant.
Read more
EU: Parliament Approves Regulation Proposal on Critical Medicines

EU: Parliament Approves Regulation Proposal on Critical Medicines

The European Parliament has approved regulatory measures aimed at strengthening the availability and supply of critical medicines in the EU.
Read more
What is a gas?

What is a gas?

You can view the answer here:
Read more
Previous
Next